Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 13/20 | 0.39 |
| ▸ | OXTR | P30559 | 4/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25326047 | 0.87 | ENPP2 (0.39) | ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL25324915 | 0.86 | AVPR1A (0.39) | AVPR1AOXTRAVPR2FFAR4 | |
| SCHEMBL25326743 | 0.83 | ENPP2 (0.43) | ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL30553154 | 0.82 | EPHX2 (0.38) | ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL25324325 | 0.82 | EPHX2 (0.38) | ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL25326463 | 0.80 | MGLL (0.41) | ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL25327040 | 0.79 | AVPR1A (0.33) | ENPP2ATXN2AVPR1AOXTR | |
| SCHEMBL30700539 | 0.77 | MAPT (0.39) | ENPP2ATXN2PHGDHFFAR4 | |
| SCHEMBL25324777 | 0.76 | LMNA (0.39) | — | |
| SCHEMBL25325289 | 0.75 | OPRL1 (0.40) | ENPP2ATXN2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | claimed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | claimed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4469446-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023144160-A1 | NEW HETEROCYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | ENPP2 3934/4885ATXN2 1263/4885AVPR1A 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.